Sign In
Buy EYPT
$12.25
-0.610 (-4.74%)
At Close: Jul 31, 2026
EyePoint Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 2, 2022
07:00am, Wednesday, 26'th Oct 2022
WATERTOWN, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the live
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
04:01pm, Tuesday, 06'th Sep 2022
WATERTOWN, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the liv
EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space
12:17am, Tuesday, 30'th Aug 2022
Shares have lost 15% year to date. Durasert technology has been extensively validated and administered to over 80,000 patient eyes.
EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q2 2022 Results - Earnings Call Transcript
03:05pm, Wednesday, 03'rd Aug 2022
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants George Elston - Chief Financial Officer Nancy Lurker - President and Chief
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue Estimates
09:47am, Wednesday, 03'rd Aug 2022
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 8.77% and 2.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
07:00am, Tuesday, 02'nd Aug 2022
WATERTOWN, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the live
EyePoint Pharmaceuticals (EYPT) Soars 21.6%: Is Further Upside Left in the Stock?
06:13am, Monday, 18'th Jul 2022
EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further stre
7 Wildly Oversold Nasdaq Stocks to Buy Now
06:00am, Tuesday, 12'th Jul 2022
For speculators that are seeking the next big upside opportunity, you may consider these oversold Nasdaq stocks to buy now. The post 7 Wildly Oversold Nasdaq Stocks to Buy Now appeared first on Invest
WATERTOWN, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the
EyePoint Pharmaceuticals to Present at the H.C Wainwright Global Healthcare Investment Conference
07:00am, Tuesday, 17'th May 2022
WATERTOWN, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives
Down 18.2% in 4 Weeks, Here's Why You Should You Buy the Dip in EyePoint Pharmaceuticals (EYPT)
11:18am, Tuesday, 10'th May 2022
EyePoint Pharmaceuticals (EYPT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ear
EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q1 2022 Earnings Call Transcript
02:17pm, Wednesday, 04'th May 2022
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants George Elston - CFO Nancy Lurker - President and CEO Jay Duker - COO Scott Jo
EyePoint, Expands Pact With Betta Pharma For EYP-1901 In China, Posts Deeper Q1 Loss
12:22pm, Wednesday, 04'th May 2022
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) executed a license agreement with Betta Pharmaceuticals Co Ltd to develop and commercialize EYP-1901 in Mainland China, Hong Kong, Macau, and Taiwan.
EyePoint Pharma Secures $45M Credit Facilities For Debt Refinancing
05:18pm, Wednesday, 09'th Mar 2022 Benzinga
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT ) has secured senior secured credit facilities of $45 million from Silicon Valley Bank to replace its existing credit facility with CRG Servicing LLC . Under the terms of the new agreement, a $30 million term loan facility and an asset-based revolving credit … Full story available on Benzinga.com
EyePoint Pharmaceuticals signs loan agreement for $45M with Silicon Valley Bank
12:47pm, Wednesday, 09'th Mar 2022 Seeking Alpha
EyePoint Pharmaceuticals (EYPT) entered into a loan agreement providing for senior secured credit facilities in the amount of $45M with Silicon Valley Bank to replace its existing…
